CLINICAL TRIALS PROFILE FOR PF-06651600

Clinical Trials for PF-06651600

Trial ID	Title	Status	Sponsor	Phase	Summary
NCT02309827 ↗	Safety and Pharmacokinetic Study of PF-06651600 in Healthy Volunteers	Completed	Pfizer	Phase 1	This study is a first in human study of PF-06651600. PF-06651600 is being developed for treatment of inflammatory bowel disease. This study will test single and multiple doses of PF-06651600. The goal of the study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of PF-06651600 in healthy volunteers.
NCT02684760 ↗	Bioavailability Study Of PF-06651600 In Healthy Subjects	Completed	Pfizer	Phase 1	PF-06651600 is being developed for treatment of inflammatory bowel disease. This study will test the bioavailability of a solid dose formulation of PF-06651600 compared to an oral solution formulation under fasting conditions and the effect of a high fat meal on the bioavailability of the solid dose formulation of PF-06651600 in healthy subjects. Safety and tolerability of the tablet and oral solution formulations of PF-06651600 will be assessed under fasting and fed conditions.
NCT02958865 ↗	Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative Colitis	Completed	Pfizer	Phase 2	The purpose of this study is to determine whether PF-06651600 and PF-06700841 are effective in treatment of moderate to severe ulcerative colitis.
NCT02969044 ↗	Study To Assess The Efficacy And Safety Of Pf-06651600 In Subjects With Rheumatoid Arthritis With An Inadequate Response To Methotrexate	Completed	Pfizer	Phase 2	This is an 8 week study to assess the efficacy and safety profile of PF-06651600 in seropositive subjects with rheumatoid arthritis with an inadequate response to methotrexate (up to approximately 50% of subjects may also have had an inadequate response to 1 anti-TNF biologic).
NCT02974868 ↗	Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata	Completed	Pfizer	Phase 2	This is a Phase 2a, randomized, double blind, parallel group, multicenter study with an extension period. The study will have a maximum duration of approximately 113 weeks. This includes an up to 5 weeks Screening Period, a 24 week Treatment Period, a 4 week Drug Holiday (#1), an up to 12 month Single Blind (investigator open, sponsor open and subject blind) Extension Period, a 4 week drug holiday (#2), a 6 month Cross Over Open Label Extension Period and a 4 week Follow up Period.
NCT03232905 ↗	Safety and Pharmacokinetic Study of PF-06651600 in Japanese Healthy Volunteers	Completed	Pfizer	Phase 1	This study is a phase 1 study of PF-06651600. PF-06651600 is being developed for treatment of inflammatory bowel disease. The goal of the study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of PF-06651600 after multiple oral doses of PF-06651600 in Japanese healthy volunteers.

Clinical Trial Conditions for PF-06651600

Condition Name

Condition Name for
Intervention	Trials
Healthy Volunteers	7
Healthy Participants	7
Healthy	6
Alopecia Areata	4

Condition MeSH

Condition MeSH for
Intervention	Trials
Alopecia Areata	5
Alopecia	5
Arthritis, Rheumatoid	2
Arthritis	2

Clinical Trial Locations for PF-06651600

Trials by Country

Trials by Country for
Location	Trials
United States	131
Canada	24
Australia	18
China	15
Spain	15

Trials by US State

Trials by US State for
Location	Trials
Connecticut	13
Florida	12
New York	9
California	8
Texas	7

Clinical Trial Progress for PF-06651600

Clinical Trial Phase

Clinical Trial Phase for
Clinical Trial Phase	Trials
Phase 3	2
Phase 2	9
Phase 1	23

Clinical Trial Status

Clinical Trial Status for
Clinical Trial Phase	Trials
Completed	23
Recruiting	7
Not yet recruiting	2

Clinical Trial Sponsors for PF-06651600

Sponsor Name

Sponsor Name for
Sponsor	Trials
Pfizer	34
Emma Guttman	1
Icahn School of Medicine at Mount Sinai	1

Sponsor Type

Sponsor Type for
Sponsor	Trials
Industry	34
Other	2